- Home
- PCRX
as 04-18-2025 1:41pm EST
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
| Founded: | 2006 | Country: | United States |
| Employees: | N/A | City: | TAMPA |
| Market Cap: | 1.1B | IPO Year: | 2011 |
| Target Price: | $30.11 | AVG Volume (30 days): | 1.2M |
| Analyst Decision: | Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.15 | EPS Growth: | N/A |
| 52 Week Low/High: | $11.16 - $31.67 | Next Earning Date: | 05-06-2025 |
| Revenue: | $700,966,000 | Revenue Growth: | 3.85% |
| Revenue Growth (this year): | 9.48% | Revenue Growth (next year): | 11.31% |
Latest Pacira BioSciences Inc. News
PCRX Breaking Stock News: Dive into PCRX Ticker-Specific Updates for Smart Investing
GlobeNewswire
a day ago
Pacira BioSciences Reaffirms Commitment to Enhancing Value for All Shareholders
Argus Research
3 days ago
PCRX: Lowering target price to $27.00
Insider Monkey
4 days ago
Is Pacira BioSciences, Inc. (PCRX) the Best Pharma Stock to Buy for Long Term Growth?
GlobeNewswire
8 days ago
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Zacks
9 days ago
The Zacks Analyst Blog Highlights Pacira Biosciences, Edgewise, Sarepta Therapeutics, Amgen and Bristol Myers Squibb
Zacks
10 days ago
Biotech Stock Roundup: PCRX Up on Patent News, EWTX Down on Study Data & More
TipRanks
10 days ago
Pacira price target raised to $28 from $25 at Truist
Argus Research
10 days ago
PCRX: Raising target price to $29.00
Compare PCRX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PCRX Pacira BioSciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.